Blue Bees Therapeutics addresses the field of immune modulators to treat cancers, using revolutionary immune response potentiation technology
Bees Therapeutics first lead candidate, BB10x, targets Fc-gamma receptors (FcgR).
FcgR was selected as our first target since it is expressed by cells derived from the myeloid
lineage as well as NK cells and B-lymphocytes. Thus, it allows us to impact a
large panel of immune cells involved in tumor control or progression. As FcgR-mediated cell-regulation proceeds through Ab
binding via its Fc domain, BB10x lead candidate contains a Fc
fragment of human IgG1 fused to a HSPG-binding ligand, or pHSL.
showed its ability to impact tumor-growth as assessed using different syngeneic models. Furthermore,
profiling of the tumor mivro-environment in syngeneic models showed that BB10x treatment impacts the
MDSC/T-cell ratio, shifting it from a MDSC-high/T-cell-low immunosuppressive
content to a MDSC-low/T-cell-high characteristic of an inflamed immunotype more
prone to tumor control.